Though programmed death-ligand 1 (PD-L1), microsatellite instability (MSI), and tumor mutational burden (TMB) are potential biomarkers that can select patients in solid tumors like colorectal cancer and non-small cell lung cancer (NSCLC) who are likely to benefit from immune checkpoint inhibitor (ICI) therapy. This evidence concerns the gene CD274 and neoplasm.